Free tool
FAERS Monitor: Salonpas
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022029 or its brand name (Salonpas, Menthol, Methyl Salicylate). Reports on generic versions are filed under their own applications.
Reports
37,817
Serious
29,306
77% of reports
Hospitalization
14,137
Death reported
7,326
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective8,004
- pain7,680
- fatigue7,245
- rheumatoid arthritis6,543
- rash6,293
- abdominal discomfort6,172
- off label use6,019
- systemic lupus erythematosus6,006
- alopecia5,903
- glossodynia5,881
- pemphigus5,836
- swelling5,561
- joint swelling5,406
- hand deformity5,363
- arthropathy5,355
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 432 |
| 2005 | 490 |
| 2006 | 454 |
| 2007 | 606 |
| 2008 | 749 |
| 2009 | 561 |
| 2010 | 794 |
| 2011 | 1,184 |
| 2012 | 905 |
| 2013 | 330 |
| 2014 | 391 |
| 2015 | 620 |
| 2016 | 1,082 |
| 2017 | 1,194 |
| 2018 | 1,762 |
| 2019 | 1,883 |
| 2020 | 2,343 |
| 2021 | 3,135 |
| 2022 | 3,363 |
| 2023 | 3,470 |
| 2024 | 5,038 |
| 2025 | 4,363 |
| 2026 | 2,666 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,016,342 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 5,836 | 485.7 | 469.6 | 1,506,946 |
| hand deformitySignal | 5,363 | 383.7 | 371.2 | 1,211,557 |
| glossodyniaSignal | 5,881 | 197.8 | 192.3 | 849,873 |
| systemic lupus erythematosusSignal | 6,006 | 113.1 | 110.2 | 555,138 |
| arthropathySignal | 5,355 | 59.2 | 57.6 | 277,476 |
| swellingSignal | 5,561 | 35.1 | 34.2 | 173,878 |
| rheumatoid arthritisSignal | 6,543 | 34.0 | 33.2 | 198,238 |
| joint swellingSignal | 5,406 | 26.0 | 25.4 | 124,976 |
| abdominal discomfortSignal | 6,172 | 21.2 | 20.7 | 115,364 |
| alopeciaSignal | 5,903 | 17.2 | 16.8 | 88,197 |
| rashSignal | 6,293 | 8.1 | 7.9 | 39,610 |
| painSignal | 7,680 | 7.0 | 6.9 | 40,392 |
| fatigueSignal | 7,245 | 5.2 | 5.1 | 25,387 |
| off label useSignal | 6,019 | 3.8 | 3.8 | 13,113 |
| drug ineffectiveSignal | 8,004 | 3.4 | 3.3 | 14,316 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.